IL311166A - dosage regimen - Google Patents

dosage regimen

Info

Publication number
IL311166A
IL311166A IL311166A IL31116624A IL311166A IL 311166 A IL311166 A IL 311166A IL 311166 A IL311166 A IL 311166A IL 31116624 A IL31116624 A IL 31116624A IL 311166 A IL311166 A IL 311166A
Authority
IL
Israel
Prior art keywords
peg3
carboxy
aib
isoglu
compound
Prior art date
Application number
IL311166A
Other languages
English (en)
Hebrew (he)
Inventor
Mikkel Askj?R Agersnap
Original Assignee
Zealand Pharma As
Mikkel Askj?R Agersnap
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Mikkel Askj?R Agersnap filed Critical Zealand Pharma As
Publication of IL311166A publication Critical patent/IL311166A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL311166A 2021-09-03 2022-09-02 dosage regimen IL311166A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21194879 2021-09-03
EP22160234 2022-03-04
PCT/EP2022/074420 WO2023031380A1 (en) 2021-09-03 2022-09-02 Dosage regime

Publications (1)

Publication Number Publication Date
IL311166A true IL311166A (en) 2024-04-01

Family

ID=84272918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311166A IL311166A (en) 2021-09-03 2022-09-02 dosage regimen

Country Status (11)

Country Link
US (1) US20250073311A1 (enExample)
EP (1) EP4392054A1 (enExample)
JP (1) JP7860224B2 (enExample)
KR (1) KR20240058121A (enExample)
AU (1) AU2022339044A1 (enExample)
CA (1) CA3228429A1 (enExample)
CL (1) CL2024000647A1 (enExample)
IL (1) IL311166A (enExample)
MX (1) MX2024002600A (enExample)
TW (1) TW202315882A (enExample)
WO (1) WO2023031380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
AU2017373901B2 (en) 2016-12-09 2021-06-03 Zealand Pharma A/S GLP-1/GLP-2 dual agonists
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
IL301891A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
TWI921427B (zh) * 2020-12-16 2026-04-11 丹麥商西蘭製藥公司 Glp-1/glp-2雙重促效劑之醫藥組合物

Also Published As

Publication number Publication date
TW202315882A (zh) 2023-04-16
EP4392054A1 (en) 2024-07-03
CL2024000647A1 (es) 2024-09-13
KR20240058121A (ko) 2024-05-03
US20250073311A1 (en) 2025-03-06
CA3228429A1 (en) 2023-03-09
AU2022339044A1 (en) 2024-03-14
JP7860224B2 (ja) 2026-05-15
WO2023031380A1 (en) 2023-03-09
WO2023031380A9 (en) 2024-02-22
MX2024002600A (es) 2024-03-22
JP2024533153A (ja) 2024-09-12

Similar Documents

Publication Publication Date Title
US11395847B2 (en) Acylated GLP-1/GLP-2 dual agonists
AU2011206979B2 (en) Treatment of cardiac conditions
EP3551652B1 (en) Glp-1/glp-2 dual agonists
US20250073311A1 (en) Dosage regime
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
CN104812772A (zh) 胰高血糖素类似物
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
CN117979986A (zh) 给药方案
CA3043151C (en) Acylated glp-1/glp-2 dual agonists
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
HK40007709B (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists